Organic Letters
Letter
prepared droplets of PFD 15, PFOB 17, PFt-BuCy 18, and 7:3
PFD 15/PFTPA 16 (20 wt % fluorous solvent) containing 13
stabilized by Pluronic F-68 (2.8 wt %) in phosphate buffered
saline (PBS) (Scheme S2). As a control, we also prepared
containing 14 for efficiency comparison (Figure S3). All
emulsions were 160−190 nm in size with polydispersities of
0.06−0.07 (Figure S1). We incubated each of the emulsions
with A375 melanoma cells for 3 h, at which point excess
emulsions were washed away and the cells underwent light
treatment for 0, 10, or 30 min. The degree of cell death was
quantified by immediate treatment with propidium iodide and
analysis by flow cytometry. We found that all emulsions
containing branched porphyrin 13 displayed no dark toxicity
and equivalent levels of cell death, greatly expanding the
fluorous solvents that can be employed for photodynamic
therapy with perfluorocarbon nanoemulsions. Ultimately, we
envision that optimized versions of these nanomaterials can be
systemically administered and accumulate at disease sites for
light-mediated therapies.
In summary, we have developed a route to a library of
biocompatible branched fluorous tags with two C6F13 chains.
These tags are derived from ethyl cyanoacetate 1 and
(perfluorohexyl)ethyl iodide 2 to provide modular building
block 3 with two functional handles and high fluorous content.
We converted 3 to eight branched fluorous tags with distinct
functionalities, including azides, aldehydes, and thiols for
standard click chemistries. We employed the thiol tag for
nucleophilic aromatic substitution to prepare fluorous
porphyrin 13. We demonstrate that 13 is more soluble in
fluorous solvent than its linear counterpart 14, facilitating the
incorporation of 13 into stable perfluorocarbon nanoemul-
sions. The high solubility of 13 in readily cleared, volatile
fluorous solvents allowed for photodynamic therapy to be
carried out with PFC nanoemulsions composed of clinically
relevant fluorous solvents. Looking forward, the simple,
modular synthesis of branched fluorous tags from readily
available starting materials will provide the community with
biocompatible methods to impart fluorous content to
molecules and materials, allowing the unique properties of
perfluorocarbons to continue to be exploited.
ACKNOWLEDGMENTS
■
M.A.M. is supported by the Chemistry-Biology Interface
Training Program (5T32GM008496). This work was
supported by shared instrumentation grants from the NSF
(CHE-1048804) and the NIH (1S10OD016387-01). Further
funding was provided by UCLA start-up funds and ACS-PRF
57379-DNI4.
REFERENCES
■
́
(1) Gladysz, J. A.; Curran, D. P.; Horvath, I. T. Handbook of Fluorous
Chemistry; Wiley-VHC: Weinheim, 2004.
(2) Vincent, J. M. Recent Advances of Fluorous Chemistry in
Material Sciences. Chem. Commun. 2012, 48, 11382−11391.
(3) Ameduri, B.; Boutevin, B. Well-Architectured Fluoropolymers:
Synthesis, Properties and Applications; Elsevier: Oxford, 2004.
(4) Riess, J. G. Understanding the Fundamentals of Perfluor-
ocarbons and Perfluorocarbon Emulsions Relevant to in Vivo Oxygen
Delivery. Artif. Cells. Blood Substit. Immobil. Biotechnol. 2005, 33, 47−
63.
(5) Horvath, I. T.; Rabai, J. Facile Catalyst Separation Without
Water: Fluorous Biphase Hydroformylation of Olefins. Science 1994,
266, 72−75.
(6) Brittain, S. M.; Ficarro, S. B.; Brock, A.; Peters, E. C. Enrichment
and Analysis of Peptide Subsets Using Fluorous Affinity Tags and
Mass Spectrometry. Nat. Biotechnol. 2005, 23, 463−468.
(7) Ko, K. S.; Jaipuri, F. A.; Pohl, N. L. Fluorous-Based
Carbohydrate Microarrays. J. Am. Chem. Soc. 2005, 127, 13162−
13163.
(8) Vegas, A. J.; Bradner, J. E.; Tang, W.; McPherson, O. M.;
Greenberg, E. F.; Koehler, A. N.; Schreiber, S. L. Fluorous-Based
Small-Molecule Microarrays for the Discovery of Histone Deacetylase
Inhibitors. Angew. Chem., Int. Ed. 2007, 46, 7960−7964.
(9) Flynn, G. E.; Withers, J. M.; Macias, G.; Sperling, J. R.; Henry, S.
L.; Cooper, J. M.; Burley, G. A.; Clark, A. W. Reversible DNA Micro-
Patterning Using the Fluorous Effect. Chem. Commun. 2017, 53,
3094−3097.
(10) Dafik, L.; Kalsani, V.; Leung, A. K. L.; Kumar, K. Fluorinated
Lipid Constructs Permit Facile Passage of Molecular Cargo into
Living Cells. J. Am. Chem. Soc. 2009, 131, 12091−12093.
(11) Zamora, C. Y.; Dafik, L.; Kumar, K. Chemical Biology Using
Fluorinated Building Blocks. In Supramolecular Chemistry: From
Molecules to Nanomaterials; John Wiley & Sons: Chichester, 2012.
(12) Sletten, E. M.; Swager, T. M. Fluorofluorophores: Fluorescent
Fluorous Chemical Tools Spanning the Visible Spectrum. J. Am.
Chem. Soc. 2014, 136, 13574−13577.
(13) Day, R. A.; Estabrook, D. A.; Logan, J. K.; Sletten, E. M.
Fluorous Photosensitizers Enhance Photodynamic Therapy with
Perfluorocarbon Nanoemulsions. Chem. Commun. 2017, 53, 13043−
13046.
(14) Kiss, L. E.; Kovesdi, I.; Rabai, J. An Improved Design of
Fluorophilic Molecules: Prediction of the Ln P Fluorous Partition
Coefficient, Fluorophilicity, Using 3D QSAR Descriptors and Neural
Networks. J. Fluorine Chem. 2001, 108, 95−109.
ASSOCIATED CONTENT
■
S
* Supporting Information
The Supporting Information is available free of charge on the
Schemes S1 and S2, Table S1, Figures S1−S4, syntheses,
characterization, and experimental procedures for all
(15) Rocaboy, C.; Hampel, F.; Gladysz, J. A. Syntheses and
Reactivities of Disubstituted and Trisubstituted Fluorous Pyridines
with High Fluorous Phase Affinities: Solid State, Liquid Crystal, and
Ionic Liquid-Phase Properties. J. Org. Chem. 2002, 67, 6863−6870.
(16) Krafft, M. P.; Riess, J. G. Per- and Polyfluorinated Substances
(PFASs): Environmental Challenges. Curr. Opin. Colloid Interface Sci.
2015, 20, 192−212.
(17) Krafft, M. P.; Riess, J. G. Selected Physicochemical Aspects of
Poly- and Perfluoroalkylated Substances Relevant to Performance,
Environment and Sustainability-Part One. Chemosphere 2015, 129, 4−
19.
AUTHOR INFORMATION
■
Corresponding Author
ORCID
Notes
(18) Langhals, H.; Ismael, R.; Yuruk, O. Persistent Fluorescence of
Perylene Dyes by Steric Inhibition of Aggregation. Tetrahedron 2000,
56, 5435−5441.
The authors declare no competing financial interest.
D
Org. Lett. XXXX, XXX, XXX−XXX